{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:05:09Z","timestamp":1792717509028,"version":"4.5.0"},"reference-count":309,"publisher":"American Diabetes Association","issue":"4","license":[{"start":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T00:00:00Z","timestamp":1626739200000},"content-version":"vor","delay-in-days":4493,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,4,1]]},"DOI":"10.2337\/db09-9028","type":"journal-article","created":{"date-parts":[[2009,3,31]],"date-time":"2009-03-31T18:23:30Z","timestamp":1238523810000},"page":"773-795","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":2479,"title":["From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus"],"prefix":"10.2337","volume":"58","author":[{"given":"Ralph A.","family":"DeFronzo","sequence":"first","affiliation":[{"name":"From the Diabetes Division, University of Texas Health Science Center, San Antonio, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","reference":[{"key":"2022051616312075700_B1","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2337\/diab.37.6.667","article-title":"Lilly Lecture: The triumvirate: \u03b2-cell, muscle, liver: a collusion responsible for NIDDM","volume":"37","author":"DeFronzo","year":"1988","journal-title":"Diabetes"},{"key":"2022051616312075700_B2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/BF01219323","article-title":"The relationship of insulin response to a glucose stimulus over a wide range of glucose tolerance","volume":"15","author":"Zimmet","year":"1978","journal-title":"Diabetologia"},{"key":"2022051616312075700_B3","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/S0140-6736(89)92804-3","article-title":"Sequential changes in serum insulin concentration during development of non-insulin-dependent diabetes","volume":"i","author":"Saad","year":"1989","journal-title":"Lancet"},{"key":"2022051616312075700_B4","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJM198805123181901","article-title":"Impaired glucose tolerance as a disorder of insulin action: longitudinal and cross-sectional studies in Pima Indians","volume":"318","author":"Lillioja","year":"1988","journal-title":"N Engl J Med"},{"key":"2022051616312075700_B5","doi-asserted-by":"crossref","first-page":"909","DOI":"10.7326\/0003-4819-113-12-909","article-title":"Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents","volume":"113","author":"Warram","year":"1990","journal-title":"Ann Intern Med"},{"key":"2022051616312075700_B6","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/0140-6736(92)92814-V","article-title":"Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study","volume":"340","author":"Martin","year":"1992","journal-title":"Lancet"},{"key":"2022051616312075700_B7","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJM198812083192302","article-title":"The natural history of impaired glucose tolerance in the Pima Indians","volume":"319","author":"Saad","year":"1988","journal-title":"N Engl J Med"},{"key":"2022051616312075700_B8","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/0026-0495(90)90168-C","article-title":"Impaired glucose tolerance and diabetes in obesity: a 6 year follow-up study of glucose metabolism","volume":"39","author":"Jallut","year":"1990","journal-title":"Metabolism"},{"key":"2022051616312075700_B9","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.2337\/diab.41.12.1575","article-title":"The metabolic profile of NIDDM is fully established in glucose-tolerant offspring of two Mexican-American NIDDM parents","volume":"41","author":"Gulli","year":"1992","journal-title":"Diabetes"},{"key":"2022051616312075700_B10","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.2337\/diab.44.12.1386","article-title":"Decreased insulin secretion and increased insulin resistance are independently related to the 7-year risk of NIDDM in Mexican-Americans","volume":"44","author":"Haffner","year":"1995","journal-title":"Diabetes"},{"key":"2022051616312075700_B11","first-page":"1846","article-title":"Insulin secretion and resistance in nondiabetic Mexican Americans and non-Hispanic whites with a parental history of diabetes","volume":"81","author":"Haffner","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2022051616312075700_B12","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1056\/NEJM199312303292703","article-title":"Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus","volume":"329","author":"Lillioja","year":"1993","journal-title":"N Engl J Med"},{"key":"2022051616312075700_B13","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.2337\/diab.45.10.1367","article-title":"Insulin levels and the natural history of glucose intolerance in Nauruans","volume":"45","author":"Dowse","year":"1996","journal-title":"Diabetes"},{"key":"2022051616312075700_B14","doi-asserted-by":"crossref","first-page":"166","DOI":"10.2337\/diabetes.54.1.166","article-title":"Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes","volume":"54","author":"Lyssenko","year":"2005","journal-title":"Diabetes"},{"key":"2022051616312075700_B15","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2337\/diacare.24.1.89","article-title":"Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development","volume":"24","author":"Weyer","year":"2001","journal-title":"Diabetes Care"},{"key":"2022051616312075700_B16","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJM198908103210601","article-title":"Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus","volume":"321","author":"Eriksson","year":"1989","journal-title":"N Engl J Med"},{"key":"2022051616312075700_B17","first-page":"177","article-title":"Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes","volume":"5","author":"DeFronzo","year":"1997","journal-title":"Diabetes Rev"},{"key":"2022051616312075700_B18","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.mcna.2004.04.013","article-title":"Pathogenesis of type 2 diabetes mellitus","volume":"88","author":"DeFronzo","year":"2004","journal-title":"Med Clin North Am"},{"key":"2022051616312075700_B19","doi-asserted-by":"crossref","first-page":"E92","DOI":"10.1152\/ajpendo.00617.2005","article-title":"Muscle glucose transport and phosphorylation in type 2 diabetic, obese non-diabetic, and genetically predisposed individuals","volume":"292","author":"Pendergrass","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2022051616312075700_B20","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s11892-008-0033-y","article-title":"Genes and type 2 diabetes mellitus","volume":"8","author":"Groop","year":"2008","journal-title":"Current Diab Reports"},{"key":"2022051616312075700_B21","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1073\/pnas.92.4.983","article-title":"Decreased muscle glucose transport\/phosphorylation is an early defect in the pathogenesis of non-insulin-dependent diabetes mellitus","volume":"92","author":"Rothman","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022051616312075700_B22","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.2337\/diabetes.50.11.2572","article-title":"Skeletal muscle insulin resistance in normoglycemic subjects with a strong family history of type 2 diabetes is associated with decreased insulin-stimulated IRS-1 tyrosine phosphorylation","volume":"50","author":"Pratipanawatr","year":"2001","journal-title":"Diabetes"},{"key":"2022051616312075700_B23","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1172\/JCI25151","article-title":"Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents","volume":"115","author":"Morino","year":"2005","journal-title":"J Clin Invest"},{"key":"2022051616312075700_B24","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.2337\/diabetes.52.10.2461","article-title":"A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes","volume":"52","author":"Kashyap","year":"2003","journal-title":"Diabetes"},{"key":"2022051616312075700_B25","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/0026-0495(89)90129-7","article-title":"Fasting hyperglycemia in non-insulin dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake","volume":"38","author":"DeFronzo","year":"1989","journal-title":"Metabolism"},{"key":"2022051616312075700_B26","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1172\/JCI114142","article-title":"Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus: evidence for multiple sites of insulin resistance","volume":"84","author":"Groop","year":"1989","journal-title":"J Clin Invest"},{"key":"2022051616312075700_B27","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0026-0495(88)90033-9","article-title":"The disposal of an oral glucose load in patients with non-insulin dependent diabetes","volume":"37","author":"Ferrannini","year":"1988","journal-title":"Metabolism"},{"key":"2022051616312075700_B28","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1172\/JCI111938","article-title":"Effects of insulin on peripheral and splanchnic glucose metabolism in non-insulin-dependent (type II) diabetes mellitus","volume":"76","author":"DeFronzo","year":"1985","journal-title":"J Clin Invest"},{"key":"2022051616312075700_B29","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1172\/JCI109394","article-title":"Insulin sensitivity and insulin binding in maturity onset diabetes","volume":"63","author":"DeFronzo","year":"1979","journal-title":"J Clin Invest"},{"key":"2022051616312075700_B30","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1467-789X.2007.00432.x","article-title":"The fundamental drivers of the obesity epidemic","volume":"9","author":"James","year":"2008","journal-title":"Obesity Rev"},{"key":"2022051616312075700_B31","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1172\/JCI109108","article-title":"Insulin binding to monocytes and insulin action in human obesity, starvation, and refeeding","volume":"62","author":"DeFronzo","year":"1978","journal-title":"J Clin Invest"},{"key":"2022051616312075700_B32","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/dmr.5610010407","article-title":"Physical training and insulin sensitivity","volume":"1","author":"Koivisto","year":"1986","journal-title":"Diabetes Metab Rev"},{"key":"2022051616312075700_B33","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1177\/107155769500200507","article-title":"Reciprocal variation in insulin-stimulated glucose uptake and pancreatic insulin secretion in women with normal glucose tolerance","volume":"2","author":"Diamond","year":"1995","journal-title":"J Soc Gynecol Invest"},{"key":"2022051616312075700_B34","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1046\/j.1365-2362.32.s3.5.x","article-title":"The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes","volume":"32","author":"Bergman","year":"2002","journal-title":"Eur J Clin Invest"},{"key":"2022051616312075700_B35","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/0026-0495(90)90168-C","article-title":"Impaired glucose tolerance and diabetes in obesity: a 6-year follow-up study of glucose metabolism","volume":"39","author":"Jallut","year":"1990","journal-title":"Metabolism"},{"key":"2022051616312075700_B36","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"key":"2022051616312075700_B37","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/(SICI)1096-9136(199804)15:4<290::AID-DIA570>3.0.CO;2-M","article-title":"Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study","volume":"15","author":"Levy","year":"1998","journal-title":"Diabet Med"},{"key":"2022051616312075700_B38","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.dsx.2007.02.004","article-title":"The relative contribution of insulin resistance and beta cell failure to the transition from normal to impaired glucose tolerance varies in different ethnic groups","volume":"1","author":"Abdul-Ghani","year":"2007","journal-title":"Diabete Metab Synd"},{"key":"2022051616312075700_B39","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00125-003-1263-9","article-title":"Beta cell dysfunction and glucose intolerance: results from the San Antonio Metabolism (SAM) study","volume":"47","author":"Gastaldelli","year":"2004","journal-title":"Diabetologia"},{"key":"2022051616312075700_B40","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1210\/jc.2004-1133","article-title":"Beta cell function in subjects spanning the range from normal glucose tolerance to overt diabetes mellitus: a new analysis","volume":"90","author":"Ferrannini","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2022051616312075700_B41","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.2337\/db05-1200","article-title":"Insulin secretion and insulin action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study (VAGES)","volume":"55","author":"Abdul-Ghani","year":"2006","journal-title":"Diabetes"},{"key":"2022051616312075700_B42","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.2337\/dc05-2179","article-title":"Contributions of \u03b2-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose","volume":"29","author":"Abdul-Ghani","year":"2006","journal-title":"Diabetes Care"},{"key":"2022051616312075700_B43","first-page":"p. 43","article-title":"Beta-cell function and insulin secretion","volume-title":"Ellenberg Rifkin's Diabetes Mellitus","author":"Ahren","year":"2003"},{"key":"2022051616312075700_B44","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/BF00265404","article-title":"Relationship between glucose tolerance, insulin secretion, and insulin action in non-obese individuals with varying degrees of glucose tolerance","volume":"32","author":"Reaven","year":"1989","journal-title":"Diabetologia"},{"key":"2022051616312075700_B45","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.2337\/diab.38.12.1512","article-title":"Lilly Lecture: Toward physiological understanding of glucose tolerance: minimal-model approach","volume":"38","author":"Bergman","year":"1989","journal-title":"Diabetes"},{"key":"2022051616312075700_B46","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.2337\/dc08-S055","article-title":"Diagnosis and classification of diabetes mellitus","volume":"31","author":"American Diabetes Association","year":"2008","journal-title":"Diabetes Care"},{"key":"2022051616312075700_B47","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2337\/diabetes.52.1.102","article-title":"\u03b2-Cell deficit and increased \u03b2-cell apoptosis in humans with type 2 diabetes","volume":"52","author":"Butler","year":"2003","journal-title":"Diabetes"},{"key":"2022051616312075700_B48","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1464-5491.2007.02043.x","article-title":"The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program","volume":"24","author":"Diabetes Prevention Program Research Group","year":"2007","journal-title":"Diabet Med"},{"key":"2022051616312075700_B49","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.2337\/dc06-9912","article-title":"Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy","volume":"29","author":"Nathan","year":"2006","journal-title":"Diabetes Care"},{"key":"2022051616312075700_B50","doi-asserted-by":"crossref","first-page":"464","DOI":"10.2337\/dc07-1796","article-title":"Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA\/KORA Augsburg Surveys S2 and S3","volume":"31","author":"Ziegler","year":"2008","journal-title":"Diabetes Care"},{"key":"2022051616312075700_B51","first-page":"415","article-title":"Lifestyle intervention for pre-diabetic neuropathy","volume":"6","author":"Smith","year":"2006","journal-title":"Diabetes Care"},{"key":"2022051616312075700_B52","first-page":"13","article-title":"Insulin response during the oral glucose tolerance test: the role of age, sex, body fat and the pattern of fat distribution","volume":"8","author":"Muller","year":"1996","journal-title":"Aging"},{"key":"2022051616312075700_B53","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/j.1532-5415.1982.tb05662.x","article-title":"Effect of age on glucose tolerance, insulin secretion, and in vivo insulin action","volume":"30","author":"Rosenthal","year":"1982","journal-title":"J Am Geriatrics Soc"},{"key":"2022051616312075700_B54","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.1152\/ajpendo.00366.2002","article-title":"Aging and insulin secretion","volume":"284","author":"Chang","year":"2003","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2022051616312075700_B55","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.2337\/diabetes.50.8.1828","article-title":"Low acute insulin secretory responses in adult offspring of people with early onset type 2 diabetes","volume":"50","author":"Gautier","year":"2001","journal-title":"Diabetes"},{"key":"2022051616312075700_B56","first-page":"86","article-title":"Defects in insulin secretion and insulin action in non-insulin-dependent diabetes mellitus are inherited. Metabolic studies on offspring of diabetic probands","volume":"100","author":"Vauhkonen","year":"1997","journal-title":"J Clin Invest"},{"key":"2022051616312075700_B57","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1172\/JCI117715","article-title":"Insulin secretion, insulin action, and hepatic glucose production in identical twins discordant for non-insulin-dependent diabetes mellitus","volume":"95","author":"Vaag","year":"1995","journal-title":"J Clin Invest"},{"key":"2022051616312075700_B58","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1136\/bmj.282.6277.1656","article-title":"Metabolic studies in unaffected co-twins of non-insulin-dependent diabetics","volume":"282","author":"Barnett","year":"1981","journal-title":"BMJ"},{"key":"2022051616312075700_B59","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000022865","article-title":"Familiarity of quantitative metabolic traits in Finnish families with non-insulin-dependent diabetes mellitus: Finland-United States Investigation of NIDDM Genes (FUSION) Study Investigators","volume":"39","author":"Watanabe","year":"1999","journal-title":"Hum Hered"},{"key":"2022051616312075700_B60","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/ng1732","article-title":"Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes","volume":"38","author":"Grant","year":"2006","journal-title":"Nat Genet"},{"key":"2022051616312075700_B61","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/ng1960","article-title":"Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution","volume":"39","author":"Helgason","year":"2007","journal-title":"Nat Genet"},{"key":"2022051616312075700_B62","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/ng2043","article-title":"A variant in CDKAL1 influences insulin response and risk of type 2 diabetes","volume":"39","author":"Steinthorsdottir","year":"2007","journal-title":"Nat Genet"},{"key":"2022051616312075700_B63","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1172\/JCI30706","article-title":"Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes","volume":"117","author":"Lyssenko","year":"2007","journal-title":"J Clin Invest"},{"key":"2022051616312075700_B64","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.2337\/db06-0474","article-title":"Transcription factor TCF7L2 genetic study in the French population: expression in human \u03b2-cells and adipose tissue and strong association with type 2 diabetes","volume":"55","author":"Cauchi","year":"2006","journal-title":"Diabetes"},{"key":"2022051616312075700_B65","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.tem.2008.08.004","article-title":"Wnt signaling: relevance to \u03b2-cell biology and diabetes","volume":"19","author":"Welters","year":"2008","journal-title":"Trends Endocrinol Metab"},{"key":"2022051616312075700_B66","doi-asserted-by":"crossref","first-page":"863","DOI":"10.2337\/diab.44.8.863","article-title":"Lipotoxicity in the pathogenesis of obesity-dependent NIDDM: genetic and clinical implications","volume":"44","author":"Unger","year":"1995","journal-title":"Diabetes"},{"key":"2022051616312075700_B67","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1172\/JCI29103","article-title":"Islet beta cell failure in type 2 diabetes","volume":"116","author":"Prentki","year":"2006","journal-title":"J Clin Invest"},{"key":"2022051616312075700_B68","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.2337\/diabetes.52.10.2461","article-title":"A sustained increase in plasma free fatty acids impairs insulin secretion in non-diabetic subjects genetically predisposed to develop type 2 diabetes","volume":"52","author":"Kashyap","year":"2003","journal-title":"Diabetes"},{"key":"2022051616312075700_B69","doi-asserted-by":"crossref","first-page":"11513","DOI":"10.1073\/pnas.96.20.11513","article-title":"Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats","volume":"96","author":"Higa","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022051616312075700_B70","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.2337\/diabetes.53.11.2844","article-title":"Pioglitazone reduces islet triglyceride content and restores impaired glucose-stimulated insulin secretion in heterozygous peroxisome proliferator-activated receptor-\u03b3\u2013deficient mice on a high-fat diet","volume":"53","author":"Matsui","year":"2004","journal-title":"Diabetes"},{"key":"2022051616312075700_B71","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1074\/jbc.273.6.3547","article-title":"Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats","volume":"273","author":"Shimabukuro","year":"1998","journal-title":"J Biol Chem"},{"key":"2022051616312075700_B72","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s001250051041","article-title":"Lowering fatty acids potentiates acute insulin response in first degree relatives of people with type II diabetes","volume":"41","author":"Paolisso","year":"1998","journal-title":"Diabetologia"},{"key":"2022051616312075700_B73","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.2337\/diabetes.51.5.1437","article-title":"Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that \u03b2-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated","volume":"51","author":"Lupi","year":"2002","journal-title":"Diabetes"},{"key":"2022051616312075700_B74","doi-asserted-by":"crossref","first-page":"E560","DOI":"10.1152\/ajpendo.00561.2002","article-title":"Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARgamma2 in the modulation of insulin secretion","volume":"286","author":"Lupi","year":"2004","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2022051616312075700_B75","doi-asserted-by":"crossref","first-page":"E871","DOI":"10.1152\/ajpendo.00551.2006","article-title":"Thiazolidinediones improve beta-cell function in type 2 diabetic patients","volume":"292","author":"Gastaldelli","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2022051616312075700_B76","doi-asserted-by":"crossref","first-page":"610","DOI":"10.2337\/diacare.13.6.610","article-title":"Glucose toxicity (Review)","volume":"13","author":"Rossetti","year":"1990","journal-title":"Diabetes Care"},{"key":"2022051616312075700_B77","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1172\/JCI113157","article-title":"Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats","volume":"80","author":"Rossetti","year":"1987","journal-title":"J Clin Invest"},{"key":"2022051616312075700_B78","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.2337\/diabetes.51.9.2749","article-title":"Role of ATP production and uncoupling protein-2 in the insulin secretory defect induced by chronic exposure to high glucose or free fatty acids and effects of peroxisome proliferator\u2013activated receptor-\u03b3 inhibition","volume":"51","author":"Patane","year":"2002","journal-title":"Diabetes"},{"key":"2022051616312075700_B79","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1210\/en.2003-0939","article-title":"Activation of the hexosamine pathway leads to phosphorylation of insulin receptor substrate-1 on Ser307 and Ser612 and impairs the phosphatidylinositol 3-kinase\/Akt\/mammalian target of rapamycin insulin biosynthetic pathway in RIN pancreatic beta-cells","volume":"145","author":"Andreozzi","year":"2004","journal-title":"Endocrinology"},{"key":"2022051616312075700_B80","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1172\/JCI112389","article-title":"Chronic hyperglycemia is associated with impaired glucose influence on insulin secretion: a study in normal rats using chronic in vivo glucose infusions","volume":"77","author":"Leahy","year":"1986","journal-title":"J Clin Invest"},{"key":"2022051616312075700_B81","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2337\/diab.36.4.459","article-title":"Impaired insulin secretion associated with near normoglycemia: study in normal rats with 96-h in vivo glucose infusions","volume":"36","author":"Leahy","year":"1987","journal-title":"Diabetes"},{"key":"2022051616312075700_B82","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2337\/diab.34.3.222","article-title":"The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus","volume":"34","author":"Garvey","year":"1985","journal-title":"Diabetes"},{"key":"2022051616312075700_B83","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/BF01228297","article-title":"Increase in insulin response after treatment of overt maturity-onset diabetes is independent of the mode of treatment","volume":"18","author":"Kosaka","year":"1980","journal-title":"Diabetologia"},{"key":"2022051616312075700_B84","doi-asserted-by":"crossref","first-page":"634","DOI":"10.2337\/diab.33.7.634","article-title":"Insulin therapy in obese, non-insulin-dependent diabetes induces improvements in insulin action and secretion that are maintained for two weeks after insulin withdrawal","volume":"33","author":"Andrews","year":"1984","journal-title":"Diabetes"},{"key":"2022051616312075700_B85","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/BF00400933","article-title":"Islet amyloid polypeptide plasma concentrations in individuals at increased risk of developing type 2 (non-insulin-dependent) diabetes mellitus","volume":"35","author":"Eriksson","year":"1992","journal-title":"Diabetologia"},{"key":"2022051616312075700_B86","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJM198908243210806","article-title":"Islet amyloid, islet-amyloid polypeptide, and diabetes mellitus","volume":"321","author":"Johnson","year":"1989","journal-title":"N Engl J Med"},{"key":"2022051616312075700_B87","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/0006-291X(89)92529-1","article-title":"Islet amyloid polypeptide inhibits glucose-stimulated insulin secretion from isolated rat pancreatic islets","volume":"160","author":"Ohsawa","year":"1989","journal-title":"Biochem Biophy Res Com"},{"key":"2022051616312075700_B88","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/BF00297454","article-title":"Altered islet amyloid polypeptide (amylin) gene expression in rat models of diabetes","volume":"32","author":"Bretherton-Watt","year":"1989","journal-title":"Diabetologia"},{"key":"2022051616312075700_B89","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1210\/er.2007-0037","article-title":"Islet amyloid in type 2 diabetes and the toxic oligomer hypothesis","volume":"29","author":"Haataja","year":"2008","journal-title":"Endocr Rev"},{"key":"2022051616312075700_B90","doi-asserted-by":"crossref","first-page":"899","DOI":"10.2337\/db07-0790","article-title":"Physiological and molecular determinants of insulin action in the baboon","volume":"57","author":"Chavez","year":"2008","journal-title":"Diabetes"},{"key":"2022051616312075700_B91","first-page":"A439","article-title":"Fasting plasma glucose (FPG) and HbA1c predict quantitatively baboon pancreatic islet amyloidosis (PIA): a novel non-human primate model of \u03b2-cell failure in type 2 diabetes mellitus (T2DM) (Abstract)","volume":"57","author":"Mendoza","year":"2008","journal-title":"Diabetes"},{"key":"2022051616312075700_B92","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ygeno.2006.03.020","article-title":"A second-generation genetic linkage map of the baboon (Papio hamadryas) genome","volume":"88","author":"Cox","year":"2006","journal-title":"Genomics"},{"key":"2022051616312075700_B93","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.2337\/db07-0197","article-title":"High expression rates of human islet amyloid polypeptide induce endoplasmic reticulum stress mediated \u03b2-cell apoptosis, a characteristic of humans with type 2 but not type 1 diabetes","volume":"56","author":"Huang","year":"2007","journal-title":"Diabetes"},{"key":"2022051616312075700_B94","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2337\/db06-0734","article-title":"Human islet amyloid polypeptide oligomers disrupt cell coupling, induce apoptosis, and impair insulin secretion in isolated human islets","volume":"56","author":"Ritzel","year":"2007","journal-title":"Diabetes"},{"key":"2022051616312075700_B95","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/BF00404025","article-title":"Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans","volume":"34","author":"Hartter","year":"1991","journal-title":"Diabetologia"},{"key":"2022051616312075700_B96","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/BF00285291","article-title":"Co-localization of islet amyloid polypeptide and insulin in the beta cell secretory granules of the human pancreatic islets","volume":"32","author":"Lukinius","year":"1989","journal-title":"Diabetologia"},{"key":"2022051616312075700_B97","doi-asserted-by":"crossref","first-page":"6678","DOI":"10.1210\/jc.2005-0079","article-title":"Activation of peroxisome proliferator-activated receptor-gamma by rosiglitazone protects human islet cells against human islet amyloid polypeptide toxicity by a phosphatidylinositol 3\u2032-kinase-dependent pathway","volume":"90","author":"Lin","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2022051616312075700_B98","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2006.01.004","article-title":"The biology of incretin hormones","volume":"3","author":"Drucker","year":"2006","journal-title":"Cell Metab"},{"key":"2022051616312075700_B99","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"2022051616312075700_B100","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s11892-006-0034-7","article-title":"Incretins and the development of type 2 diabetes","volume":"6","author":"Meier","year":"2006","journal-title":"Curren Diab Reports"},{"key":"2022051616312075700_B101","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1210\/jcem.86.8.7750","article-title":"Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients","volume":"86","author":"Toft-Nielsen","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2022051616312075700_B102","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/BF02427280","article-title":"Reduced incretin effect in type 2 (non-insulin-dependent) diabetes","volume":"29","author":"Nauck","year":"1986","journal-title":"Diabetologia"},{"key":"2022051616312075700_B103","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00125-005-0107-1","article-title":"Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005","volume":"49","author":"Holst","year":"2006","journal-title":"Diabetologia"},{"key":"2022051616312075700_B104","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1172\/JCI116186","article-title":"Preserved incretin activity of glucagon-like peptide 1 [7\u201336 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus","volume":"91","author":"Nauck","year":"1993","journal-title":"J Clin Invest"},{"key":"2022051616312075700_B105","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.2337\/diabetes.50.11.2497","article-title":"Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes","volume":"50","author":"Meier","year":"2001","journal-title":"Diabetes"},{"key":"2022051616312075700_B106","doi-asserted-by":"crossref","first-page":"380","DOI":"10.2337\/diabetes.52.2.380","article-title":"The influence of GLP-1 on glucose-stimulated insulin secretion: effects on \u03b2-cell sensitivity in type 2 and nondiabetic subjects","volume":"52","author":"Kjems","year":"2003","journal-title":"Diabetes"},{"key":"2022051616312075700_B107","doi-asserted-by":"crossref","first-page":"E199","DOI":"10.1152\/ajpendo.00545.2003","article-title":"Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans","volume":"287","author":"Holst","year":"2004","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2022051616312075700_B108","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1007\/BF00274255","article-title":"The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with type 2 (non-insulin-dependent) diabetes mellitus","volume":"32","author":"Jones","year":"1989","journal-title":"Diabetologia"},{"key":"2022051616312075700_B109","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00125-008-1195-5","article-title":"Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes","volume":"52","author":"Hojberg","year":"2009","journal-title":"Diabetologia"},{"key":"2022051616312075700_B110","first-page":"1015","article-title":"Regulation of intermediatory metabolism during fasting and refeeding. Chapter 52","volume-title":"Endocrinology","author":"DeFronzo","year":"2006"},{"key":"2022051616312075700_B111","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1172\/JCI112078","article-title":"Mechanism of liver glycogen repletion in vivo by nuclear magnetic resonance spectroscopy","volume":"76","author":"Shulman","year":"1985","journal-title":"J Clin Invest"},{"key":"2022051616312075700_B112","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/0026-0495(87)90031-X","article-title":"Insulin action in non-insulin-dependent diabetes mellitus: the relationship between hepatic and extrahepatic insulin resistance and obesity","volume":"36","author":"Firth","year":"1987","journal-title":"Metabolism"},{"key":"2022051616312075700_B113","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0026-0495(88)90023-6","article-title":"Quantification of the relative impairment in actions of insulin on hepatic glucose production and peripheral glucose uptake in non-insulin-dependent diabetes mellitus","volume":"37","author":"Campbell","year":"1988","journal-title":"Metabolism"},{"key":"2022051616312075700_B114","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1172\/JCI113572","article-title":"Relationship between plasma glucose and insulin concentration, glucose production, and glucose disposal in normal subjects and patients with non-insulin-dependent diabetes","volume":"82","author":"Chen","year":"1988","journal-title":"J Clin Invest"},{"key":"2022051616312075700_B115","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.2337\/diab.43.12.1440","article-title":"Relationship between hepatic glucose production and fasting plasma glucose concentration in patients with NIDDM","volume":"43","author":"Jeng","year":"1994","journal-title":"Diabetes"},{"key":"2022051616312075700_B116","doi-asserted-by":"crossref","first-page":"990","DOI":"10.2337\/diab.35.9.990","article-title":"Effects of weight loss on mechanisms of hyperglycemia in obese non-insulin-dependent diabetes mellitus","volume":"35","author":"Henry","year":"1986","journal-title":"Diabetes"},{"key":"2022051616312075700_B117","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/dmr.5610030204","article-title":"Regulation of hepatic glucose metabolism in humans","volume":"3","author":"DeFronzo","year":"1987","journal-title":"Diabetes Metab Rev"},{"key":"2022051616312075700_B118","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1172\/JCI115997","article-title":"Increased rate of gluconeogenesis in type II diabetes mellitus: a 13C nuclear magnetic resonance study","volume":"90","author":"Magnusson","year":"1992","journal-title":"J Clin Invest"},{"key":"2022051616312075700_B119","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1172\/JCI114940","article-title":"Mechanism of increased gluconeogenesis in noninsulin-dependent diabetes mellitus: role of alterations in systemic, hepatic, and muscle lactate and alanine metabolism","volume":"86","author":"Consoli","year":"1990","journal-title":"J Clin Invest"},{"key":"2022051616312075700_B120","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1053\/meta.2002.34700","article-title":"Glucagon dose response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals","volume":"51","author":"Matsuda","year":"2002","journal-title":"Metabolism"},{"key":"2022051616312075700_B121","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1172\/JCI106297","article-title":"Studies of pancreatic \u03b1-cell function in normal and diabetic subjects","volume":"49","author":"Unger","year":"1970","journal-title":"J Clin Invest"},{"key":"2022051616312075700_B122","doi-asserted-by":"crossref","first-page":"274","DOI":"10.2337\/diab.36.3.274","article-title":"Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics","volume":"36","author":"Baron","year":"1987","journal-title":"Diabetes"},{"key":"2022051616312075700_B123","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.2337\/diabetes.49.8.1367","article-title":"Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study","volume":"49","author":"Gastaldelli","year":"2000","journal-title":"Diabetes"},{"key":"2022051616312075700_B124","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2337\/diabetes.49.6.969","article-title":"Glucose-6-phosphatase flux in vitro is increased in type 2 diabetes","volume":"49","author":"Clore","year":"2000","journal-title":"Diabetes"},{"key":"2022051616312075700_B125","first-page":"E214","article-title":"The glucose clamp technique: a method for quantifying insulin secretion and resistance","volume":"237","author":"DeFronzo","year":"1979","journal-title":"Am J Physiol"},{"key":"2022051616312075700_B126","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S1071-3581(03)00520-8","article-title":"Metabolic and molecular basis of insulin resistance","volume":"10","author":"Bajaj","year":"2003","journal-title":"J Nuclear Cardiol"},{"key":"2022051616312075700_B127","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2337\/diab.37.12.1595","article-title":"Banting Lecture: Role of insulin resistance in human disease","volume":"37","author":"Reaven","year":"1988","journal-title":"Diabetes"},{"key":"2022051616312075700_B128","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1172\/JCI110350","article-title":"Receptor and postreceptor defects contribute to the insulin resistance in noninsulin-dependent diabetes mellitus","volume":"68","author":"Kolterman","year":"1981","journal-title":"J Clin Invest"},{"key":"2022051616312075700_B129","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0026-0495(88)90023-6","article-title":"Quantification of the relative impairment in actions of insulin on hepatic glucose production and peripheral glucose uptake in non-insulin-dependent diabetes mellitus","volume":"37","author":"Campbell","year":"1988","journal-title":"Metabolism"},{"key":"2022051616312075700_B130","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1172\/JCI111533","article-title":"Relationships between insulin secretion, insulin action, and fasting plasma glucose concentration in nondiabetic and noninsulin-dependent diabetic subjects","volume":"74","author":"Bogardus","year":"1984","journal-title":"J Clin Invest"},{"key":"2022051616312075700_B131","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/BF01338715","article-title":"Peripheral glucose metabolism in control subjects and diabetic patients during glucose, glucose-insulin, and insulin sensitivity tests","volume":"1","author":"Butterfield","year":"1965","journal-title":"Diabetologia"},{"key":"2022051616312075700_B132","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/00005792-196311000-00002","article-title":"Roles of insulin and growth hormone, based on studies of forearm metabolism in man","volume":"42","author":"Zierler","year":"1963","journal-title":"Medicine"},{"key":"2022051616312075700_B133","doi-asserted-by":"crossref","first-page":"915","DOI":"10.2337\/diab.45.7.915","article-title":"Roles of glucose transport and glucose phosphorylation in muscle insulin resistance of NIDDM","volume":"45","author":"Bonadonna","year":"1996","journal-title":"Diabetes"},{"key":"2022051616312075700_B134","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1172\/JCI115686","article-title":"31P nuclear magnetic resonance measurements of muscle glucose-6-phosphate: evidence for reduced insulin-dependent muscle glucose transport or phosphorylation activity in non-insulin-dependent diabetes mellitus","volume":"89","author":"Rothman","year":"1992","journal-title":"J Clin Invest"},{"key":"2022051616312075700_B135","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1056\/NEJM199907223410404","article-title":"Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes","volume":"341","author":"Cline","year":"1999","journal-title":"N Engl J Med"},{"key":"2022051616312075700_B136","first-page":"E701","article-title":"Regulation of hexokinase II and glycogen synthase mRNA, protein, and activity in human muscle","volume":"269","author":"Mandarino","year":"1995","journal-title":"Am J Physiol"},{"key":"2022051616312075700_B137","first-page":"230","article-title":"Effects of insulin on subcellular localization of hexokinase II in human skeletal muscle in vivo","volume":"83","author":"Vogt","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2022051616312075700_B138","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1172\/JCI113118","article-title":"Effects of insulin infusion on human skeletal muscle pyruvate dehydrogenase, phosphofructokinase, and glycogen synthase: evidence for their role in oxidative and nonoxidative glucose metabolism","volume":"80","author":"Mandarino","year":"1987","journal-title":"J Clin Invest"},{"key":"2022051616312075700_B139","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1056\/NEJM199001253220403","article-title":"Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy","volume":"322","author":"Shulman","year":"1990","journal-title":"N Engl J Med"},{"key":"2022051616312075700_B140","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1210\/jcem-72-1-96","article-title":"The role of free fatty acid metabolism in the pathogensis of insulin resistance in obesity and non-insulin dependent diabetes mellitus","volume":"72","author":"Groop","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"2022051616312075700_B141","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.2337\/diab.36.11.1341","article-title":"Role of lipid oxidation in the pathogenesis of insulin resistance of obesity and type II diabetes","volume":"36","author":"Felber","year":"1987","journal-title":"Diabetes"},{"key":"2022051616312075700_B142","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/dmr.5610040803","article-title":"Metabolic basis of obesity and non-insulin dependent diabetes mellitus","volume":"4","author":"Golay","year":"1988","journal-title":"Diabetes\/Metab Rev"},{"key":"2022051616312075700_B143","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1172\/JCI7535","article-title":"Insulin resistance differentially affects the PI 3-kinase and MAP kinase-mediated signaling in human muscle","volume":"105","author":"Cusi","year":"2000","journal-title":"J Clin Invest"},{"key":"2022051616312075700_B144","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/414799a","article-title":"Insulin signalling and the regulation of glucose and lipid metabolism","volume":"414","author":"Saltiel","year":"2001","journal-title":"Nature"},{"key":"2022051616312075700_B145","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nrm1837","article-title":"Critical nodes in signaling pathways: insight into insulin action","volume":"7","author":"Tanijuchi","year":"2006","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2022051616312075700_B146","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1385\/ENDO:29:1:73","article-title":"Insulin resistance and improvements in signal transduction","volume":"29","author":"Musi","year":"2006","journal-title":"Endocrine"},{"key":"2022051616312075700_B147","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3132\/dvdr.2007.001","article-title":"The insulin resistance syndrome: physiological considerations","volume":"4","author":"Kashyap","year":"2007","journal-title":"Diabetes Vasc Dis Res"},{"key":"2022051616312075700_B148","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1210\/jc.2004-0745","article-title":"Insulin resistance is associated with impaired nitric oxide synthase (NOS) activity in skeletal muscle of type 2 diabetic subjects","volume":"90","author":"Kashyap","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2022051616312075700_B149","doi-asserted-by":"crossref","first-page":"30392","DOI":"10.1074\/jbc.M103702200","article-title":"Insulin-stimulated activation of eNOS is independent of Ca2+ but requires phosphorylation by Akt at Ser(1179)","volume":"276","author":"Montagnani","year":"2001","journal-title":"J Biol Chem"},{"key":"2022051616312075700_B150","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.2337\/diabetes.52.8.1943","article-title":"Rosiglitazone improves downstream insulin-receptor signaling in type 2 diabetic patients","volume":"52","author":"Miyazaki","year":"2003","journal-title":"Diabetes"},{"key":"2022051616312075700_B151","doi-asserted-by":"crossref","first-page":"E537","DOI":"10.1152\/ajpendo.00541.2003","article-title":"Discordant effects of a chronic physiological increase in plasma FFA on insulin signaling in healthy subjects with or without a family history of type 2 diabetes","volume":"287","author":"Kashyap","year":"2004","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2022051616312075700_B152","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.2337\/diabetes.50.11.2572","article-title":"Skeletal muscle insulin resistance in normoglycemic subjects with a strong family history of type 2 diabetes is associated with decreased insulin-stimulated IRS-1 tyrosine phosphorylation","volume":"50","author":"Pratipanawatr","year":"2001","journal-title":"Diabetes"},{"key":"2022051616312075700_B153","doi-asserted-by":"crossref","first-page":"284","DOI":"10.2337\/diabetes.49.2.284","article-title":"Characterization of signal transduction and glucose transport in skeletal muscle from type 2 diabetic patients","volume":"49","author":"Krook","year":"2000","journal-title":"Diabetes"},{"key":"2022051616312075700_B154","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2337\/diabetes.51.2.443","article-title":"Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects","volume":"51","author":"Kim","year":"2002","journal-title":"Diabetes"},{"key":"2022051616312075700_B155","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1172\/JCI0214955","article-title":"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes","volume":"109","author":"Hundal","year":"2002","journal-title":"J Clin Invest"},{"key":"2022051616312075700_B156","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.2337\/diabetes.52.6.1319","article-title":"Reduced activation of phosphatidylinositol-3 kinase and increased serine 636 phosphorylation of insulin receptor substrate-1 in primary culture of skeletal muscle cells from patients with type 2 diabetes","volume":"52","author":"Bouzakri","year":"2003","journal-title":"Diabetes"},{"key":"2022051616312075700_B157","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.2337\/diabetes.53.11.2735","article-title":"Molecular mechanisms of insulin resistance that impact cardiovascular biology","volume":"53","author":"Wang","year":"2004","journal-title":"Diabetes"},{"key":"2022051616312075700_B158","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.2337\/db06-0391","article-title":"Molecular mechanisms of insulin resistance: serine phosphorylation of insulin receptor substrate-1 and increased expression of p85\u03b1: the two sides of a coin","volume":"55","author":"Draznin","year":"2006","journal-title":"Diabetes"},{"key":"2022051616312075700_B159","doi-asserted-by":"crossref","first-page":"21J","DOI":"10.1016\/S0002-9149(99)00353-7","article-title":"Insulin signaling in the arterial wall","volume":"84","author":"Hsueh","year":"1999","journal-title":"Am J Cardiol"},{"key":"2022051616312075700_B160","doi-asserted-by":"crossref","first-page":"284","DOI":"10.2337\/diabetes.49.2.284","article-title":"Characterization of signal transduction and glucose transport in skeletal muscle from type 2 diabetic patients","volume":"49","author":"Krook","year":"2000","journal-title":"Diabetes"},{"key":"2022051616312075700_B161","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.2337\/diacare.25.7.1177","article-title":"Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study","volume":"25","author":"Hanley","year":"2002","journal-title":"Diabetes Care"},{"key":"2022051616312075700_B162","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2337\/diacare.24.4.683","article-title":"Cardiovascular morbidity and mortality associated with the metabolic syndrome","volume":"24","author":"Isomaa","year":"2001","journal-title":"Diabetes Care"},{"key":"2022051616312075700_B163","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.2337\/diabetes.54.11.3252","article-title":"Insulin resistance, the metabolic syndrome, and incident cardiovascular events in the Framingham Offspring Study","volume":"54","author":"Rutter","year":"2005","journal-title":"Diabetes"},{"key":"2022051616312075700_B164","doi-asserted-by":"crossref","first-page":"318","DOI":"10.2337\/dc06-0919","article-title":"Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in Caucasian subjects from the general population: the Bruneck study","volume":"30","author":"Bonora","year":"2007","journal-title":"Diabetes Care"},{"key":"2022051616312075700_B165","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S1047-2797(98)00002-7","article-title":"Ability of alternative indices of insulin sensitivity to predict cardiovascular risk: comparison with the \u201cminimal model\u201d: Insulin Resistance Atherosclerosis Study (IRAS) Investigators","volume":"8","author":"Howard","year":"1998","journal-title":"Ann Epidemiol"},{"key":"2022051616312075700_B166","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2337\/diacare.25.7.1135","article-title":"HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study","volume":"25","author":"Bonora","year":"2002","journal-title":"Diabetes Care"},{"key":"2022051616312075700_B167","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1001\/jama.296.21.joc60158","article-title":"Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial","volume":"296","author":"Mazzone","year":"2006","journal-title":"JAMA"},{"key":"2022051616312075700_B168","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1001\/jama.299.13.1561","article-title":"Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial","volume":"299","author":"Nissen","year":"2008","journal-title":"JAMA"},{"key":"2022051616312075700_B169","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"2022051616312075700_B170","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1073\/pnas.75.10.5173","article-title":"Influence of hyperinsulinemia, hyperglycemia, and the route of glucose administration on splanchnic glucose exchange","volume":"75","author":"DeFronzo","year":"1978","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022051616312075700_B171","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/S0140-6736(78)91807-X","article-title":"Lack of gastrointestinal mediator of insulin action in maturity onset diabetes","volume":"2","author":"DeFronzo","year":"1978","journal-title":"Lancet"},{"key":"2022051616312075700_B172","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2337\/diab.32.1.35","article-title":"Regulation of splanchnic and peripheral glucose uptake by insulin and hyperglycemia","volume":"32","author":"DeFronzo","year":"1983","journal-title":"Diabetes"},{"key":"2022051616312075700_B173","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1172\/JCI111938","article-title":"Effects of insulin on peripheral and splanchnic glucose metabolism in non-insulin-dependent (type II) diabetes mellitus","volume":"76","author":"DeFronzo","year":"1985","journal-title":"J Clin Invest"},{"key":"2022051616312075700_B174","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0026-0495(88)90033-9","article-title":"The disposal of an oral glucose load in patients with non-insulin dependent diabetes","volume":"37","author":"Ferrannini","year":"1988","journal-title":"Metabolism"},{"key":"2022051616312075700_B175","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1210\/jc.2003-030723","article-title":"Role of the adipocytes, FFA, and ectopic fat in the pathogenesis of type 2 diabetes mellitus: PPAR agonists provide a rational therapeutic approach","volume":"89","author":"Bays","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2022051616312075700_B176","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1586\/14779072.6.3.343","article-title":"Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity","volume":"6","author":"Bays","year":"2008","journal-title":"Expert Rev Cardio Ther"},{"key":"2022051616312075700_B177","first-page":"112","article-title":"Glucose metabolism in obesity and type 2 diabetes","volume":"17","author":"Bonadonna","year":"1991","journal-title":"Diabete Metab"},{"key":"2022051616312075700_B178","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1368-504X.2004.00389.x","article-title":"Dysfunctional fat cells, lipotoxicity, and type 2 diabetes","volume":"143","author":"DeFronzo","year":"2004","journal-title":"Int J Clin Pract Suppl"},{"key":"2022051616312075700_B179","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1210\/jcem-61-5-807","article-title":"Ambient plasma free fatty acid concentrations in noninsulin-dependent diabetes mellitus: evidence for insulin resistance","volume":"61","author":"Fraze","year":"1985","journal-title":"J Clin Endocrinol Metab"},{"key":"2022051616312075700_B180","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1073\/pnas.56.1.247","article-title":"Mechanism for the stimulation of gluconeogenesis by fatty acids in perfused rat liver","volume":"56","author":"Williamson","year":"1966","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022051616312075700_B181","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/0026-0495(87)90051-5","article-title":"Acute elevation of free fatty acid levels leads to hepatic insulin resistance in obese subjects","volume":"36","author":"Bevilacqua","year":"1987","journal-title":"Metabolism"},{"key":"2022051616312075700_B182","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1172\/JCI111133","article-title":"Effect of fatty acids on glucose production and utilization in man","volume":"72","author":"Ferrannini","year":"1983","journal-title":"J Clin Invest"},{"key":"2022051616312075700_B183","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/0026-0495(82)90163-9","article-title":"Effect of long chain triglyceride infusion on glucose metabolism in man","volume":"31","author":"Thiebaud","year":"1982","journal-title":"Metabolism"},{"key":"2022051616312075700_B184","first-page":"153","article-title":"Effects of fat infusion on glucose tolerance and insulin plasma levels","volume":"10","author":"Felber","year":"1964","journal-title":"Int J Exp Med"},{"key":"2022051616312075700_B185","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1172\/JCI118742","article-title":"Mechanism of free fatty acid-induced insulin resistance in humans","volume":"97","author":"Roden","year":"1996","journal-title":"J Clin Invest"},{"key":"2022051616312075700_B186","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2337\/diabetes.49.3.399","article-title":"Prolonged elevation of plasma free fatty acids impairs pancreatic beta-cell function in obese nondiabetic humans but not in individuals with type 2 diabetes","volume":"49","author":"Carpentier","year":"2000","journal-title":"Diabetes"},{"key":"2022051616312075700_B187","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1172\/JCI107625","article-title":"Glucose metabolism and the response to insulin by human adipose tissue in spontaneous and experimental obesity: effects of dietary composition and adipose cell size","volume":"53","author":"Salans","year":"1974","journal-title":"J Clin Invest"},{"key":"2022051616312075700_B188","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/0026-0495(77)90061-0","article-title":"Spontaneous and experimental human obesity: effects of diet and adipose cell size on lipolysis and lipogenesis","volume":"26","author":"Bray","year":"1977","journal-title":"Metabolism"},{"key":"2022051616312075700_B189","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1046\/j.1365-2362.32.s3.3.x","article-title":"Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction","volume":"32","author":"Boden","year":"2002","journal-title":"Eur J Clin Invest"},{"key":"2022051616312075700_B190","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.2337\/diabetes.51.10.3043","article-title":"Free fatty acids reduce splanchnic and peripheral glucose uptake in patients with type 2 diabetes","volume":"51","author":"Bajaj","year":"2002","journal-title":"Diabetes"},{"key":"2022051616312075700_B191","doi-asserted-by":"crossref","first-page":"10290","DOI":"10.1074\/jbc.M408985200","article-title":"Lipid infusion induces an inflammatory\/fibrotic response and decreases expression of nuclear encoded mitochondrial genes in human skeletal muscle","volume":"280","author":"Richardson","year":"2005","journal-title":"J Biol Chem"},{"key":"2022051616312075700_B192","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1172\/JCI5001","article-title":"Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity","volume":"103","author":"Dresner","year":"1999","journal-title":"J Clin Invest"},{"key":"2022051616312075700_B193","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.2337\/diabetes.48.6.1270","article-title":"Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade","volume":"48","author":"Griffin","year":"1999","journal-title":"Diabetes"},{"key":"2022051616312075700_B194","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.2337\/diabetes.51.7.2005","article-title":"Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and I\u03baB-\u03b1","volume":"51","author":"Itani","year":"2002","journal-title":"Diabetes"},{"key":"2022051616312075700_B195","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0140-6736(63)91500-9","article-title":"The glucose fatty-acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus","volume":"1","author":"Randle","year":"1963","journal-title":"Lancet"},{"key":"2022051616312075700_B196","first-page":"E463","article-title":"Interaction of carbohydrate and fat fuels in human skeletal muscle: impact of obesity and NIDDM","volume":"270","author":"Mandarino","year":"1996","journal-title":"Am J Physiol"},{"key":"2022051616312075700_B197","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2337\/diabetes.49.5.677","article-title":"Fuel selection in human skeletal muscle in insulin resistance: a reexamination","volume":"49","author":"Kelley","year":"2000","journal-title":"Diabetes"},{"key":"2022051616312075700_B198","doi-asserted-by":"crossref","first-page":"7812","DOI":"10.1016\/S0021-9258(17)41039-8","article-title":"Mechanism of palmityl coenzyme A inhibition of liver glycogen synthase","volume":"252","author":"Wititsuwannakul","year":"1977","journal-title":"J Biol Chem"},{"key":"2022051616312075700_B199","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1042\/cs0820219","article-title":"Effect of increased free fatty acid supply on glucose metabolism and skeletal muscle glycogen synthase activity in normal man","volume":"82","author":"Johnson","year":"1992","journal-title":"Clin Science"},{"key":"2022051616312075700_B200","first-page":"A65","article-title":"In vivo glucose transport (GT) and phosphorylation (GP) in skeletal muscle are impaired by elevation of plasma FFA (Abstract)","volume":"47","author":"Pendergrass","year":"1998","journal-title":"Diabetes"},{"key":"2022051616312075700_B201","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.2337\/diabetes.54.6.1640","article-title":"Dose response effect of elevated plasma FFA on insulin signaling","volume":"54","author":"Belfort","year":"2005","journal-title":"Diabetes"},{"key":"2022051616312075700_B202","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1371\/journal.pmed.0020233","article-title":"Decreased insulin-stimulated ATP synthesis and phosphate transport in muscle of insulin-resistant offspring of type 2 diabetic parents","volume":"2","author":"Petersen","year":"2005","journal-title":"Plos Med"},{"key":"2022051616312075700_B203","doi-asserted-by":"crossref","first-page":"50230","DOI":"10.1074\/jbc.M200958200","article-title":"Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle","volume":"277","author":"Yu","year":"2002","journal-title":"J Biol Chem"},{"key":"2022051616312075700_B204","doi-asserted-by":"crossref","first-page":"E554","DOI":"10.1152\/ajpendo.2000.279.3.E554","article-title":"Long-chain acyl-CoA esters as indicators of lipid metabolism and insulin sensitivity in rat and human muscle","volume":"279","author":"Ellis","year":"2000","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2022051616312075700_B205","article-title":"Pioglitazone stimulates AMPK signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo","author":"Coletta","journal-title":"Diabetologia"},{"key":"2022051616312075700_B206","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.2337\/diabetes.54.11.3148","article-title":"Effect of sustained reduction in plasma free fatty acid concentration on intramuscular long chain-fatty acyl-CoAs and insulin action in patients with type 2 diabetes","volume":"54","author":"Bajaj","year":"2005","journal-title":"Diabetes"},{"key":"2022051616312075700_B207","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/ng0703-244","article-title":"PGC-1alpha at the crossroads of type 2 diabetes","volume":"34","author":"Attie","year":"2003","journal-title":"Nat Genet"},{"key":"2022051616312075700_B208","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1210\/er.2002-0012","article-title":"Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator","volume":"24","author":"Puigserver","year":"2003","journal-title":"Endocrine Rev"},{"key":"2022051616312075700_B209","doi-asserted-by":"crossref","first-page":"6570","DOI":"10.1073\/pnas.0401401101","article-title":"Erralpha and Gabpa\/b specify PGC-1alpha-dependent oxidative phosphorylation gene expression that is altered in diabetic muscle","volume":"101","author":"Mootha","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022051616312075700_B210","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0092-8674(00)80611-X","article-title":"Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1","volume":"98","author":"Wu","year":"1999","journal-title":"Cell"},{"key":"2022051616312075700_B211","doi-asserted-by":"crossref","first-page":"E229","DOI":"10.1152\/ajpendo.2001.280.2.E229","article-title":"DAG accumulation from saturated fatty acids desensitizes insulin stimulation of glucose uptake in muscle cells","volume":"280","author":"Montell","year":"2001","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2022051616312075700_B212","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2337\/diabetes.53.1.25","article-title":"Ceramide content is increased in skeletal muscle from obese insulin resistant humans","volume":"53","author":"Adams","year":"2004","journal-title":"Diabetes"},{"key":"2022051616312075700_B213","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2337\/db08-1228","article-title":"Plasma ceramides are elevated in obese subjects with type 2 diabetes and are associated with the level of insulin resistance","volume":"58","author":"Haus","year":"2009","journal-title":"Diabetes"},{"key":"2022051616312075700_B214","doi-asserted-by":"crossref","first-page":"10290","DOI":"10.1074\/jbc.M408985200","article-title":"Lipid infusion induces an inflammatory\/fibrotic response and decreases expression of nuclear encoded mitochondrial genes in human skeletal muscle","volume":"280","author":"Richardson","year":"2005","journal-title":"J Biol Chem"},{"key":"2022051616312075700_B215","doi-asserted-by":"crossref","first-page":"8466","DOI":"10.1073\/pnas.1032913100","article-title":"Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1","volume":"100","author":"Patti","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022051616312075700_B216","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/ng1180","article-title":"PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes","volume":"34","author":"Mootha","year":"2003","journal-title":"Nat Genet"},{"key":"2022051616312075700_B217","first-page":"E678","article-title":"Deleterious action of fatty acids on mitochondrial ATP synthsis: the link between lipotoxicity, mitochondrial dysfunction, and insulin resistance","volume":"295","author":"Abdul-Ghani","year":"2008","journal-title":"Am J Physiol"},{"key":"2022051616312075700_B218","doi-asserted-by":"crossref","first-page":"E846","DOI":"10.1152\/ajpendo.00030.2008","article-title":"Mechanisms of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes","volume":"294","author":"Cervera","year":"2008","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2022051616312075700_B219","first-page":"A404","article-title":"Improved splanchnic glucose metabolism is responsible for glycemic control in T2DM subjects treated with exenatide (Abstract)","volume":"56","author":"Cervera","year":"2007","journal-title":"Diabetes"},{"key":"2022051616312075700_B220","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2337\/db08-0515","article-title":"Inhibition of dipeptidyl peptidase-4 by vildagliptin during glucagon-like peptide-1 infusion increases liver glucose uptake in the conscious dog","volume":"58","author":"Edgerton","year":"2009","journal-title":"Diabetes"},{"key":"2022051616312075700_B221","doi-asserted-by":"crossref","first-page":"E269","DOI":"10.1152\/ajpendo.90222.2008","article-title":"Exenatide can reduce glucose independent of islet hormones or gastric emptying","volume":"295","author":"Ionut","year":"2008","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2022051616312075700_B222","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1210\/jcem-64-1-106","article-title":"Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus","volume":"64","author":"Reaven","year":"1987","journal-title":"J Clin Endocrinol Metab"},{"key":"2022051616312075700_B223","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1172\/JCI106297","article-title":"Studies of pancreatic \u03b1-cell function in normal and diabetic subjects","volume":"49","author":"Unger","year":"1970","journal-title":"J Clin Invest"},{"key":"2022051616312075700_B224","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2337\/diab.32.11.1055","article-title":"Counterregulatory hormone release and glucose recovery after hypoglycemia in non-insulin-dependent diabetic patients","volume":"32","author":"Boden","year":"1983","journal-title":"Diabetes"},{"key":"2022051616312075700_B225","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1586\/17446651.1.3.329","article-title":"Exenatide: first in class incretin mimetic for the treatment of type 2 diabetes mellitus","volume":"1","author":"Triplitt","year":"2006","journal-title":"Expert Rev Endocrinol Metab"},{"key":"2022051616312075700_B226","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1007\/s001250100006","article-title":"Effects of a novel glucagon receptor antagonist (Bay 27\u20139955) on glucagon-stimulated glucose production in humans","volume":"44","author":"Petersen","year":"2001","journal-title":"Diabetologia"},{"key":"2022051616312075700_B227","article-title":"Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus","author":"DeFronzo","journal-title":"Endocrine Practice"},{"key":"2022051616312075700_B228","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1016\/S0024-3205(01)01090-6","article-title":"Renal glucose reabsorption during hypertonic glucose infusion in female streptozotocin-induced diabetic rats","volume":"68","author":"Noonan","year":"2001","journal-title":"Life Sci"},{"key":"2022051616312075700_B229","first-page":"F283","article-title":"Molecular adaptations of GLUT1 and GLUT2 in renal proximal tubules of diabetic rats","volume":"266","author":"Dominguez","year":"1994","journal-title":"Am J Physiol"},{"key":"2022051616312075700_B230","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1681\/ASN.V86943","article-title":"Overexpression of GLUT2 gene in renal proximal tubules of diabetic Zucker rats","volume":"8","author":"Kamran","year":"1997","journal-title":"J Am Soc Nephol"},{"key":"2022051616312075700_B231","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3109\/00365517109090668","article-title":"Maximum tubular reabsorpiton capacity for glucose and renal hemodynamics during rapid hypertonic glucose infusion in normal and diabetic subjects","volume":"28","author":"Mogensen","year":"1971","journal-title":"Scan J Clin Lab Invest"},{"key":"2022051616312075700_B232","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.2337\/diabetes.54.12.3427","article-title":"Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non\u2013insulin-dependent diabetes","volume":"54","author":"Rahmoune","year":"2005","journal-title":"Diabetes"},{"key":"2022051616312075700_B233","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1001\/jama.291.23.2847","article-title":"Prevalence of overweight and obesity among US children, adolescents, and adults, 1999\u20132002","volume":"291","author":"Hedley","year":"2004","journal-title":"JAMA"},{"key":"2022051616312075700_B234","doi-asserted-by":"crossref","first-page":"S155","DOI":"10.2337\/db06-S019","article-title":"Central regulation of energy homeostasis","volume":"55","author":"Porte","year":"2006","journal-title":"Diabetes"},{"key":"2022051616312075700_B235","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/35007534","article-title":"Central nervous system control of food intake","volume":"404","author":"Schwartz","year":"2000","journal-title":"Nature"},{"key":"2022051616312075700_B236","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1126\/science.289.5487.2122","article-title":"Role of brain insulin receptor in control of body weight and reproduction","volume":"289","author":"Bruning","year":"2000","journal-title":"Science"},{"key":"2022051616312075700_B237","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1172\/JCI29063","article-title":"Central insulin action in energy and glucose homeostasis","volume":"116","author":"Plum","year":"2006","journal-title":"J Clin Invest"},{"key":"2022051616312075700_B238","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/diabetes.48.9.1801","article-title":"Altered hypothalamic function in response to glucose ingestion in obese humans","volume":"48","author":"Matsuda","year":"1999","journal-title":"Diabetes"},{"key":"2022051616312075700_B239","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nn0602-861","article-title":"Decreasing hypothalamic insulin receptors causes hyperphagia and insulin resistance in rats","volume":"5","author":"Obici","year":"2002","journal-title":"Nat Neurosci"},{"key":"2022051616312075700_B240","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1172\/JCI200112954","article-title":"Central melanocortin receptors regulate insulin action","volume":"108","author":"Obici","year":"2001","journal-title":"J Clin Invest"},{"key":"2022051616312075700_B241","first-page":"4059","article-title":"Metabolic effects of metformin on glucose and lactate metabolism in NIDDM","volume":"81","author":"Cusi","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2022051616312075700_B242","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1056\/NEJM199508313330902","article-title":"Efficacy of metformin in patients with non-insulin dependent diabetes mellitus","volume":"333","author":"DeFronzo","year":"1995","journal-title":"N Engl J Med"},{"key":"2022051616312075700_B243","first-page":"89","article-title":"Metformin: a review of its metabolic effects","volume":"6","author":"Cusi","year":"1998","journal-title":"Diabetes Reviews"},{"key":"2022051616312075700_B244","doi-asserted-by":"crossref","first-page":"710","DOI":"10.2337\/diacare.24.4.710","article-title":"Improved glycemic control and enhanced insulin sensitivity in liver and muscle in type 2 diabetic subjects treated with pioglitazone","volume":"24","author":"Miyazaki","year":"2001","journal-title":"Diabetes Care"},{"key":"2022051616312075700_B245","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1007\/s001250100031","article-title":"Effect of rosiglitazone on glucose and free fatty acid metabolism in type 2 diabetic patients","volume":"44","author":"Miyazaki","year":"2001","journal-title":"Diabetologia"},{"key":"2022051616312075700_B246","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1210\/jcem.87.6.8567","article-title":"Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients","volume":"87","author":"Miyazaki","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2022051616312075700_B247","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/sj.ijo.0802625","article-title":"Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type 2 diabetic patients","volume":"28","author":"Bajaj","year":"2004","journal-title":"Internatl J Obesity"},{"key":"2022051616312075700_B248","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.2337\/diabetes.54.11.3148","article-title":"Effects of PPAR\u03b1 and PPAR\u03b3 agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus","volume":"54","author":"Bajaj","year":"2005","journal-title":"Diabetes"},{"key":"2022051616312075700_B249","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.2337\/dc05-2445","article-title":"The effect of pioglitazone on the liver","volume":"29","author":"Gastaldelli","year":"2006","journal-title":"Diabetes Care"},{"key":"2022051616312075700_B250","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1210\/jc.2005-1159","article-title":"The effect of rosiglitazone on the liver: decreased gluconeogenesis in patients with type 2 diabetes","volume":"91","author":"Gastaldelli","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2022051616312075700_B251","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s00125-007-0698-9","article-title":"Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus","volume":"50","author":"Bajaj","year":"2007","journal-title":"Diabetologia"},{"key":"2022051616312075700_B252","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/j.1463-1326.2008.00880.x","article-title":"Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients","volume":"10","author":"Miyazaki","year":"2008","journal-title":"Diabetes Obes Metab"},{"key":"2022051616312075700_B253","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s00125-006-0141-7","article-title":"Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review","volume":"49","author":"Natali","year":"2006","journal-title":"Diabetologia"},{"key":"2022051616312075700_B254","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2337\/diabetes.51.2.443","article-title":"Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110-\u03b2 protein levels in skeletal muscle of type 2 diabetic subjects","volume":"51","author":"Kim","year":"2002","journal-title":"Diabetes"},{"key":"2022051616312075700_B255","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1172\/JCI13505","article-title":"Role of AMP-activated protein kinase in mechanism of metformin action","volume":"108","author":"Zhou","year":"2001","journal-title":"J Clin Invest"},{"key":"2022051616312075700_B256","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.2337\/diabetes.51.7.2074","article-title":"Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes","volume":"51","author":"Musi","year":"2002","journal-title":"Diabetes"},{"key":"2022051616312075700_B257","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/S0149-2918(00)83039-8","article-title":"Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group","volume":"22","author":"Einhorn","year":"2000","journal-title":"Clin Ther"},{"key":"2022051616312075700_B258","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1001\/jama.283.13.1695","article-title":"Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial","volume":"283","author":"Fonseca","year":"2000","journal-title":"JAMA"},{"key":"2022051616312075700_B259","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/dmrr.478","article-title":"Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study","volume":"21","author":"Matthews","year":"2005","journal-title":"Diab\/Metab Res Rev"},{"key":"2022051616312075700_B260","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s00125-005-1751-1","article-title":"Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes","volume":"48","author":"Charbonnel","year":"2005","journal-title":"Diabetologia"},{"key":"2022051616312075700_B261","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1056\/NEJM199803263381303","article-title":"Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus","volume":"338","author":"Inzucchi","year":"1998","journal-title":"N Engl J Med"},{"key":"2022051616312075700_B262","doi-asserted-by":"crossref","first-page":"p. 915","DOI":"10.1002\/0470862092.d0613","article-title":"Combination therapy in type 2 diabetes","volume-title":"International Textbook of Diabetes Mellitus","author":"Bajaj","year":"2004","edition":"3rd ed"},{"key":"2022051616312075700_B263","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1007\/s001250100031","article-title":"Effect of rosiglitazone on glucose and free fatty acid metabolism in type 2 diabetic patients","volume":"44","author":"Miyazaki","year":"2001","journal-title":"Diabetologia"},{"key":"2022051616312075700_B264","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1210\/jcem.87.6.8567","article-title":"Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients","volume":"87","author":"Miyazaki","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2022051616312075700_B265","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/diabetes.52.6.1364","article-title":"Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes","volume":"52","author":"Bajaj","year":"2003","journal-title":"Diabetes"},{"key":"2022051616312075700_B266","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo controlled trial of pioglitazone in patients with non-alcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N Engl J Med"},{"key":"2022051616312075700_B267","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMra041001","article-title":"Thiazolidinediones","volume":"351","author":"Yki-Jarvinen","year":"2004","journal-title":"N Engl J Med"},{"key":"2022051616312075700_B268","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","volume":"355","author":"Kahn","year":"2006","journal-title":"N Engl J Med"},{"key":"2022051616312075700_B269","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1185\/030079906X112598","article-title":"Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study","volume":"22","author":"Hanefeld","year":"2006","journal-title":"Cur Med Res Opinion"},{"key":"2022051616312075700_B270","doi-asserted-by":"crossref","first-page":"544","DOI":"10.2337\/diacare.28.3.544","article-title":"Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes","volume":"28","author":"Tan","year":"2005","journal-title":"Diabetes Care"},{"key":"2022051616312075700_B271","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1463-1326.2005.00541.x","article-title":"Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (&gt;60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study","volume":"8","author":"Rosenstock","year":"2006","journal-title":"Diab Obes Metab"},{"key":"2022051616312075700_B272","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1464-5491.2007.02160.x","article-title":"Rosiglitazone RECORD study: glucose control outcomes at 18 months","volume":"24","author":"Home","year":"2007","journal-title":"Diabet Med"},{"key":"2022051616312075700_B273","article-title":"One-year treatment with exenatide improves \u03b2-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial","author":"Bunck","journal-title":"Diabetes Care"},{"key":"2022051616312075700_B274","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2337\/diacare.28.5.1092","article-title":"Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes","volume":"28","author":"DeFronzo","year":"2005","journal-title":"Diabetes Care"},{"key":"2022051616312075700_B275","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1185\/030079908X253870","article-title":"Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years","volume":"24","author":"Klonoff","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"2022051616312075700_B276","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.2337\/diacare.25.12.2244","article-title":"Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes","volume":"25","author":"Johnson","year":"2002","journal-title":"Diabetes Care"},{"key":"2022051616312075700_B277","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1007\/s00125-006-0176-9","article-title":"Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin","volume":"49","author":"Evans","year":"2006","journal-title":"Diabetologia"},{"key":"2022051616312075700_B278","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UPKDS 34)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"key":"2022051616312075700_B279","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1001\/jama.281.21.2005","article-title":"Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group","volume":"281","author":"Turner","year":"1999","journal-title":"JAMA"},{"key":"2022051616312075700_B280","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2337\/diacare.21.1.87","article-title":"UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes","volume":"21","author":"U.K. Prospective Diabetes Diabetes Study Group","year":"1998","journal-title":"Diabetes Care"},{"key":"2022051616312075700_B281","doi-asserted-by":"crossref","first-page":"330","DOI":"10.2337\/diacare.25.2.330","article-title":"Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57)","volume":"25","author":"Wright","year":"2002","journal-title":"Diabetes Care"},{"key":"2022051616312075700_B282","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/(SICI)1096-9136(199804)15:4<297::AID-DIA572>3.0.CO;2-W","article-title":"UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group","volume":"15","author":"Matthews","year":"1998","journal-title":"Diabet Med"},{"key":"2022051616312075700_B283","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.2337\/diab.44.11.1249","article-title":"Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group","volume":"44","author":"U.K. prospective diabetes study 16","year":"1995","journal-title":"Diabetes"},{"key":"2022051616312075700_B284","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0014-2999(98)00807-3","article-title":"The biguanide compound metformin prevents desensitization of human pancreatic islets induced by high glucose","volume":"364","author":"Lupi","year":"1999","journal-title":"Eur J Pharmacol"},{"key":"2022051616312075700_B285","doi-asserted-by":"crossref","first-page":"S134","DOI":"10.2337\/diabetes.51.2007.S134","article-title":"Lipotoxicity in human pancreatic islets and the protective effect of metformin","volume":"51","author":"Lupi","year":"2002","journal-title":"Diabetes"},{"key":"2022051616312075700_B286","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2337\/diabetes.55.02.06.db05-1066","article-title":"Effect of pioglitazone on pancreatic \u03b2-cell function and diabetes risk in Hispanic women with prior gestational diabetes","volume":"55","author":"Xiang","year":"2006","journal-title":"Diabetes"},{"key":"2022051616312075700_B287","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S0140-6736(06)69420-8","article-title":"The Dream (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial","volume":"368","year":"2006","journal-title":"Lancet"},{"key":"2022051616312075700_B288","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.2337\/diabetes.54.4.1150","article-title":"Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program","volume":"54","author":"Knowler","year":"2005","journal-title":"Diabetes"},{"key":"2022051616312075700_B289","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.2337\/diabetes.51.9.2796","article-title":"Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women","volume":"51","author":"Buchanan","year":"2002","journal-title":"Diabetes"},{"key":"2022051616312075700_B290","author":"DeFronzo"},{"key":"2022051616312075700_B291","doi-asserted-by":"crossref","first-page":"E560","DOI":"10.1152\/ajpendo.00561.2002","article-title":"Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARgamma2 in the modulation of insulin secretion","volume":"286","author":"Lupi","year":"2004","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2022051616312075700_B292","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2337\/diabetes.50.5.1021","article-title":"\u03b2-Cell mass dynamics in Zucker diabetic fatty rats: rosiglitazone prevents the rise in net cell death","volume":"50","author":"Finegood","year":"2001","journal-title":"Diabetes"},{"key":"2022051616312075700_B293","doi-asserted-by":"crossref","first-page":"676","DOI":"10.2337\/diabetes.51.3.676","article-title":"Peroxisomal proliferator\u2013activated receptor-\u03b3 upregulates glucokinase gene expression in \u03b2-cells","volume":"51","author":"Kim","year":"2002","journal-title":"Diabetes"},{"key":"2022051616312075700_B294","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.2337\/diabetes.53.suppl_3.S79","article-title":"Effect of PPAR-gamma activation and inhibition on glucose-stimulated insulin release in INS-1e cells","volume":"53","author":"Santini","year":"2004","journal-title":"Diabetes"},{"key":"2022051616312075700_B295","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/BF02369349","article-title":"Effects of Troglitazone (CS-045) on insulin secretion in isolated rat pancreatic islets and HIT cells: an insulinotropic mechanism distinct from glibenclamide","volume":"38","author":"Masuda","year":"1995","journal-title":"Diabetologia"},{"key":"2022051616312075700_B296","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.2337\/diabetes.50.7.1562","article-title":"Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age","volume":"50","author":"Tourrel","year":"2001","journal-title":"Diabetes"},{"key":"2022051616312075700_B297","doi-asserted-by":"crossref","first-page":"751","DOI":"10.2337\/diabetes.52.3.751","article-title":"Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo","volume":"52","author":"Kim","year":"2003","journal-title":"Diabetes"},{"key":"2022051616312075700_B298","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.1210\/en.2003-0323","article-title":"Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets","volume":"144","author":"Farilla","year":"2003","journal-title":"Endocrinology"},{"key":"2022051616312075700_B299","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.2337\/diacare.28.8.1936","article-title":"Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year","volume":"28","author":"Ahren","year":"2005","journal-title":"Diabetes Care"},{"key":"2022051616312075700_B300","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1517\/13543784.16.4.533","article-title":"Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes","volume":"16","author":"Deacon","year":"2007","journal-title":"Expert Opin Invest Drugs"},{"key":"2022051616312075700_B301","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1210\/jc.2006-1882","article-title":"The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients","volume":"92","author":"Balas","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2022051616312075700_B302","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.2337\/diacare.26.11.3080","article-title":"The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients","volume":"26","author":"Riddle","year":"2003","journal-title":"Diabetes Care"},{"key":"2022051616312075700_B303","doi-asserted-by":"crossref","first-page":"389","DOI":"10.7326\/0003-4819-130-5-199903020-00002","article-title":"Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial","volume":"130","author":"Yki-Jarvinen","year":"1999","journal-title":"Ann Intern Med"},{"key":"2022051616312075700_B304","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1056\/NEJMoa075392","article-title":"Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes","volume":"357","author":"Holman","year":"2007","journal-title":"N Engl J Med"},{"key":"2022051616312075700_B305","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2337\/diacare.16.1.21","article-title":"Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-mo outpatient trial","volume":"16","author":"Henry","year":"1993","journal-title":"Diabetes Care"},{"key":"2022051616312075700_B306","doi-asserted-by":"crossref","first-page":"559","DOI":"10.7326\/0003-4819-143-8-200510180-00006","article-title":"Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial","volume":"143","author":"Heine","year":"2005","journal-title":"Ann Intern Med"},{"key":"2022051616312075700_B307","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.clinthera.2007.11.006","article-title":"Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial","volume":"29","author":"Barnett","year":"2007","journal-title":"Clin Thera"},{"key":"2022051616312075700_B308","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00125-006-0510-2","article-title":"A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study","volume":"50","author":"Nauck","year":"2007","journal-title":"Diabetologia"},{"key":"2022051616312075700_B309","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc08-9025","article-title":"Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"32","author":"Nathan","year":"2009","journal-title":"Diabetes Care"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.org\/diabetes\/diabetes\/article-pdf\/58\/4\/773\/303468\/zdb00409000773.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/58\/4\/773\/303468\/zdb00409000773.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T03:29:28Z","timestamp":1710214168000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/58\/4\/773\/117\/From-the-Triumvirate-to-the-Ominous-Octet-A-New"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,1]]},"references-count":309,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4,1]]}},"URL":"https:\/\/doi.org\/10.2337\/db09-9028","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,1]]}}}